EBA stress test results shed light on sovereign derivatives exposures

European bank sovereign derivatives exposures revealed

One lit bulb surrounded by darker bulbs

The size of individual European banks’ derivatives exposures to sovereign entities were published last month as part of the European Banking Authority (EBA) stress test – figures banks don’t usually report.

The largest exposure to a single sovereign is not held by a major derivatives dealer but by French bank BPCE, which is in-the-money with France to the tune of €3.8 billion. The next largest exposure to the country is held by Crédit Agricole and is €468 million.

The exposures collected by the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here